Eiger biopharmaceuticals, inc. (EIGR)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating expenses:
Research and development

9,481

11,928

14,059

12,936

12,868

12,011

13,196

6,372

5,512

7,779

6,145

8,131

7,464

9,377

8,072

10,720

4,845

3,624

2,110

2,008

375

-14,871

5,316

4,981

5,218

-11,280

4,571

4,217

2,919

General and administrative

5,241

4,584

4,247

4,225

4,057

4,082

3,643

3,237

2,994

2,806

2,727

2,946

3,522

3,532

3,264

2,477

3,833

3,087

762

577

429

-5,673

2,815

2,024

1,706

-1,753

952

775

553

Total operating expenses

14,722

16,512

18,306

17,161

16,925

16,093

16,839

9,609

8,506

10,585

8,872

11,077

10,986

12,909

11,336

13,197

8,678

6,711

2,872

2,585

804

-20,544

8,131

7,005

6,924

-13,034

5,523

4,992

3,472

Loss from operations

-14,722

-16,512

-18,306

-17,161

-16,925

-16,093

-16,839

-9,609

-8,506

-10,585

-8,872

-11,077

-10,986

-12,909

-11,336

-13,197

-8,678

-6,711

-2,872

-2,585

-804

20,544

-8,131

-7,005

-6,924

13,034

-5,523

-4,992

-3,472

Interest expense

884

888

884

869

765

755

681

495

398

395

388

378

363

5

0

0

685

-

-

-

-

-

271

0

59

-

-

-

-

Interest income

367

475

585

502

511

343

371

189

94

89

98

113

110

-

-

-

-

-

-

-

-

-

36

21

8

-

14

20

24

Other income (expense), net

-

5

-11

1

-10

4

5

0

-21

-

-8

196

-

49

-34

-4

-385

-

-

-

-

-

8

-8

-4

-

56

43

-82

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

183

-

-

-

-

Consolidated net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,162

-

-5,453

-4,929

-3,530

Net loss attributable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-35

-61

Net loss

-15,239

-16,920

-18,616

-17,527

-17,189

-16,501

-17,144

-9,915

-8,831

-10,893

-9,170

-11,146

-11,239

-12,768

-11,370

-13,201

-9,748

-

-

-

-

-

-8,358

-6,992

-

-

-5,453

-4,894

-3,469

Change in fair value of non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-3,044

-61

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,453

-7,938

-3,530

Consolidated net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,453

-4,929

-3,530

Unrealized (loss) gain on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-26

18

-2

-

5

-4

-3

Net loss and comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,872

-2,585

-804

-

-8,384

-6,974

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,164

-

-5,448

-4,933

-3,533

Net loss per common share, basic and diluted

-0.62

-0.67

-0.76

-0.75

-0.90

-0.98

-1.20

-0.82

-0.84

-1.09

-1.10

-1.33

-1.34

5.94

-1.49

-1.87

-10.42

-30.00

-14.70

-13.34

-4.15

-6.44

-0.40

-0.38

-0.60

14.22

-6.17

-8.98

-3.99

Weighted-average common shares outstanding, basic and diluted

24,501

24,127

24,437

23,408

19,168

17,706

14,255

12,045

10,529

9,811

8,372

8,367

8,360

8,400

7,622

7,069

935

273

195

193

193

-50,429

20,752

18,511

11,939

-1,877

884

884

884